Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Revenue From Contract With Customer Excluding Assessed Tax of $3.22 billion for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +12.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $317.45 million | Q3 2017: $334.15 million | Q1 2018: $373.45 million | Q2 2018: $372.85 million | Q3 2018: $391.71 million | Q1 2019: $400.75 million | Q2 2019: $387.76 million | Q3 2019: $461.10 million | Q1 2020: $502.07 million | Q2 2020: $429.49 million | Q3 2020: $476.78 million | Q1 2021: $486.03 million | Q2 2021: $501.69 million | Q3 2021: $408.74 million | Q1 2022: $519.36 million | Q2 2022: $533.80 million | Q3 2022: $505.34 million | Q1 2023: $596.42 million | Q2 2023: $595.28 million | Q3 2023: $581.33 million | Q1 2024: $648.83 million | Q2 2024: $712.03 million | Q3 2024: $745.74 million | Q1 2025: $745.15 million | Q2 2025: $825.41 million | Q3 2025: $776.13 million.
- Over the full 10 years of available data (2016 to 2025), BIOMARIN PHARMACEUTICAL INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 188.4%.
- Historical annual values: Fiscal year 2025: $3.22 billion | Fiscal year 2024: $2.85 billion | Fiscal year 2023: $2.42 billion | Fiscal year 2022: $2.10 billion | Fiscal year 2021: $1.85 billion | Fiscal year 2020: $1.86 billion | Fiscal year 2019: $1.70 billion | Fiscal year 2018: $1.49 billion | Fiscal year 2017: $1.31 billion | Fiscal year 2016: $1.12 billion.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: